Mundipharma Research Limited
- Address
- 191 Science Park, Milton Road
Sponsor Overview
Specializations
Invasive fungal disease prevention in transplant settings
Mundipharma Research Limited supports clinical research in invasive fungal diseases affecting adults undergoing allogeneic blood and marrow transplantation, with a focus on antifungal protection in highly immunocompromised patients.
- Fungal-free survival
- Allogeneic blood and marrow transplantation
- Antifungal prophylaxis
The sponsor’s activity in this area reflects interest in managing serious opportunistic infections in oncology and transplant care.
Chronic pulmonary aspergillosis in adults
The company funds research into chronic pulmonary aspergillosis, addressing adults with limited treatment options and persistent respiratory disease burden.
- Respiratory symptoms
- Computed tomography
- St George's Respiratory Questionnaire
This area includes evaluation of clinical and radiological response in a complex pulmonary fungal infection.
Paediatric antifungal therapy
Mundipharma Research Limited also supports studies in paediatric patients from birth to under 18 years who require systemic antifungal treatment or prophylaxis for suspected or confirmed infection.
- Pharmacokinetics
- Safety
- Tolerability
These studies extend interest in antifungal medicine into younger age groups with serious infectious risk.
Systemic fungal infections
The sponsor’s trial portfolio covers broader fungal infections requiring systemic treatment, including cases managed in hospital and specialist care environments.
- Invasive fungal infection
- Systemic antifungals
- Adult and paediatric care
Its research landscape is centred on antifungal treatment needs across severe respiratory, transplant-related, and multi-age patient populations.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 1, Multicentre, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single IV Dose of Rezafungin Acetate in Paediatric Subjects from Birth to <18 Years of Age, Receiving Systemic Antifungals as Prophylaxis for Invasive Fungal Infection or to Treat a Suspected or Confirmed Fungal Infection |  Germany Spain | Not Recruiting |
| Evaluation of Rezafungin Acetate for Chronic Pulmonary Aspergillosis in Patients with Limited Treatment Options: A Phase 2, Open-Label Study |  Austria Belgium France Germany Hungary Italy Spain The Netherlands | Not Recruiting |
| Phase 3 Randomized Study of Rezafungin Acetate vs. Standard Antimicrobial Regimen for Preventing Invasive Fungal Diseases in Allogeneic BMT Recipients | Belgium France Germany Italy Spain | Not Recruiting |
Data & Insights
This sponsor works with 5 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 46 sites across their trial portfolio.
Therapeutic Focus
- 1.Bacterial Infections and Mycoses3 trials180 other sponsors
Partnered Research Centres
46 centres- Address
- Avenida De Las Islas Baleares 3, 09006 Burgos
- Address
- Robert-Koch-Allee 2, 82131 Gauting
- Address
- Ruddershove 10, 8000 Bruges
- Address
- Via Paradisa 2, 56124 Pisa
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- 3 Boulevard Alexandre Fleming, 25000 Besançon
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Mundipharma Research Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.